{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:19:41Z","timestamp":1754162381160,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia Autonomous Region","doi-asserted-by":"publisher","award":["2024MS08043"],"award-info":[{"award-number":["2024MS08043"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The development of acquired endocrine resistance and reduced chemosensitivity in oestrogen receptor-positive (ER+) breast cancer presents significant challenges. Microtubule-based process-related genes (MBPRGs) play essential biological roles in the cell cycle and the development of migration. This study aimed to establish a novel prognostic signature based on MBPRGs to improve patient outcomes and offer additional treatment options for those with ER+ breast cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical data along with relevant RNA information with ER+ breast cancer were sourced from The Cancer Genome Atlas and the Molecular Taxonomy of Breast Cancer International Consortium. Consensus clustering was subsequently utilised to identify new molecular subgroups. Evaluations of the tumour immune microenvironment and immune status of these subgroups were performed via ESTIMATE, CIBERSORT, MCP, and ssGSEA. Additionally, functional analyses were conducted to investigate the underlying mechanisms involved. Prognostic risk models were developed via random forest, support vector machines and the least absolute shrinkage and selection operator algorithm. Single-cell analysis revealed differences in the expression levels of key genes among various cell types. Western blotting was used to measure protein levels in breast cancer cell lines. Immunohistochemical staining was used to assess protein expression in paraffin-embedded tissues, and Kaplan\u2013Meier survival curves were generated to evaluate survival differences between the high- and low-expression groups of key genes. Transwell and cell viability assays were used to examine the biological functions of CHORDC1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two molecular subgroups with significantly different survival outcomes were identified. Longer survival was linked to a high immune score, low tumour purity, a greater presence of immune infiltrating cells, and an overall positive immune status. Risk models derived from MBPRGs exhibited strong potential for predicting survival in patients with ER+ breast cancer. Key genes had elevated protein levels in differentiated breast cancer cell lines, and elevated CHORDC1 expression was linked to a tendency towards a worse outcome in patients with ER+ breast cancer. Silencing CHORDC1 inhibited cell viability and invasion, reducing sensitivity to tamoxifen and paclitaxel <jats:italic>in vitro<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MBPRG expression is linked to the immune microenvironment and drug resistance in ER+ breast cancer patients, providing a reliable prognostic indicator for this group.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1608991","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:28:55Z","timestamp":1753853335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of microtubule-based processes gene expression with immune microenvironment and its predictive value for drug response in oestrogen receptor-positive breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhenfeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/1178223418774802","article-title":"Breast cancer immunotherapy: an update","volume":"12","author":"Makhoul","year":"2018","journal-title":"Breast cancer: basic Clin Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.33079","article-title":"Latest overview of the cyclin-dependent kinases 4\/6 inhibitors in breast cancer: the past, the present and the future","volume":"10","author":"Chen","year":"2019","journal-title":"J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28030168","article-title":"Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer","volume":"28","author":"Andrahennadi","year":"2021","journal-title":"Curr Oncol (Toronto Ont.)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care (Basel Switzerland)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2011.11.009","article-title":"Interplay between microtubule dynamics and intracellular organization","volume":"44","author":"de Forges","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00153","article-title":"Microtubules and their role in cellular stress in cancer","volume":"4","author":"Parker","year":"2014","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20190016","article-title":"Microtubules in cell migration","volume":"63","author":"Garcin","year":"2019","journal-title":"Essays Biochem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00396-4","article-title":"Post-translational modifications of tubulin: their role in cancers and the regulation of signaling molecules","volume":"30","author":"Wattanathamsan","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0483","article-title":"Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity","volume":"11","author":"Han","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.680402","article-title":"Expression of microtubule-associated proteins in relation to prognosis and efficacy of immunotherapy in non-small cell lung cancer","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16134","DOI":"10.1038\/s41598-023-42985-3","article-title":"Identification and verification of microtubule associated genes in lung adenocarcinoma","volume":"13","author":"Wei","year":"2023","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/1574892816666211130170149","article-title":"Prognostic and therapeutic values of autophagy-related genes in triple-negative breast cancer","volume":"17","author":"Liu","year":"2022","journal-title":"Recent patents anti-cancer Drug Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2974126","article-title":"Development of an independent prognostic signature based on three hypoxia-related genes for breast cancer","volume":"2022","author":"Wang","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-022-00473-2","article-title":"Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis","volume":"29","author":"Ma","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820983298","article-title":"Key genes and prognostic analysis in HER2+ Breast cancer","volume":"20","author":"Weng","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12920-024-01814-w","article-title":"Identification of diagnostic model in heart failure with myocardial fibrosis and conduction block by integrated gene co-expression network analysis","volume":"17","author":"Yuan","year":"2024","journal-title":"BMC Med Genomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1039\/c2np20070h","article-title":"Lasso peptides: structure, function, biosynthesis, and engineering","volume":"29","author":"Maksimov","year":"2012","journal-title":"Natural product Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12935-020-01274-z","article-title":"Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma","volume":"20","author":"Guo","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.05.020","article-title":"A support vector machine-recursive feature elimination feature selection method based on artificial contrast variables and mutual information","volume":"910","author":"Lin","year":"2012","journal-title":"J chromatography. B Analytical Technol Biomed Life Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199465","article-title":"Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature","volume":"14","author":"Shen","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-632","article-title":"An expression atlas of human primary cells: inference of gene function from coexpression networks","volume":"14","author":"Mabbott","year":"2013","journal-title":"BMC Genomics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0249","article-title":"Single-cell transcriptional diversity is a hallmark of developmental potential","volume":"367","author":"Gulati","year":"2020","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00857","article-title":"Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer","volume":"12","author":"Normanno","year":"2005","journal-title":"Endocrine-related Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"16198","DOI":"10.3390\/ijms242216198","article-title":"Metastatic ER+ Breast cancer: mechanisms of resistance and future therapeutic approaches","volume":"24","author":"Raheem","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer","volume":"363","author":"Mart\u00edn","year":"2010","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2010.n.029","article-title":"A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer","volume":"10","author":"Yardley","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45207","article-title":"SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314724","article-title":"Evaluating the expression and prognostic value of genes encoding microtubule-associated proteins in lung cancer","volume":"23","author":"Singharajkomron","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijms24097781","article-title":"Machine learning models for the identification of prognostic and predictive cancer biomarkers: A systematic review","volume":"24","author":"Al-Tashi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","first-page":"1","article-title":"Machine learning in healthcare data analysis: A survey","volume":"8","author":"Dhillon","year":"2019","journal-title":"J Biol Today\u2019s World"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.03.547377","article-title":"Robust Feature Selection strategy detects a panel of microRNAs as putative diagnostic biomarkers in Breast Cancer","author":"Costa","year":"2023","journal-title":"bioRxiv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1586","article-title":"Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index","volume":"14","author":"Wang","year":"2024","journal-title":"Clin Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:28:56Z","timestamp":1753853336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1608991"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1608991","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1608991"}}